Oregon Therapeutics & Lantern Pharma Collaborate to Drive Development of First-In-Class Cancer Drug Candidate XCE853 Using AI Technology
Paris & Dallas - Lantern Pharma Inc. (NASDAQ: LTRN), a prominent pioneer in artificial intelligence (AI) driven oncology drug discovery and development, has announced a strategic alliance with French biotechnology company, Oregon Therapeutics. The collaboration aims to optimize the development of XCE853, a ground-breaking protein disulfide isomerase (PDI) inhibitor drug candidate. By utilizing Lantern Pharma’s RADR AI platform, the two entities hope to unlock the drug’s potential in treating various targeted cancer indications.
Through this collaboration, Lantern Pharma seeks to leverage its advanced AI-driven technology to expedite the development process of XCE853. By analyzing vast amounts of data, Lantern’s RADR AI platform can identify novel and targeted uses for the drug candidate in the field of cancer metabolism. This cutting-edge technology will help streamline the drug development process by identifying the most promising applications for XCE853, consequently ensuring quicker and more efficient clinical trials.
Oregon Therapeutics brings its expertise in biotechnology to the table, making this partnership a perfect synergy of innovative approaches. Together, they aim to redefine cancer treatment by revolutionizing the development of first-in-class drugs. XCE853, with its potent PDI inhibition properties, holds immense promise for disrupting cancer metabolism and combating various types of cancer.
The strategic collaboration between Lantern Pharma and Oregon Therapeutics is expected to usher in a new era of targeted cancer therapies. By combining Lantern Pharma’s advanced AI technology and Oregon Therapeutics’ biotechnology expertise, the partnership aims to accelerate the discovery of novel indications for XCE853. This collaboration has the potential to redefine the future of cancer treatment, offering hope to patients worldwide.
Comments